Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 12/20 | 0.50 |
| ▸ | MEP1A | Q16819 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.48 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746079 | 0.85 | MEP1B (0.46) | MEP1BMEP1AMEN1KMT2ATRPM8 | |
| SCHEMBL13434071 | 0.84 | KMT2A (0.70) | MEN1KMT2ARAB9ASMN1; SMN2ATM | |
| SCHEMBL13227060 | 0.82 | KMT2A (0.51) | MEP1BMEN1KMT2AATM | |
| SCHEMBL20794226 | 0.81 | MEP1B (0.54) | MEP1BMEP1AMEN1KMT2AADAM10 | |
| SCHEMBL20780312 | 0.79 | MEP1B (0.51) | MEP1BMEP1AMRGPRX4TP53PKM | |
| SCHEMBL168738 | 0.74 | FOLH1 (0.59) | MEP1BMEP1AMEN1KMT2AMRGPRX4 | |
| SCHEMBL29630981 | 0.74 | FOLH1 (0.59) | MEP1BMEP1AMEN1KMT2AMRGPRX4 | |
| SCHEMBL10127537 | 0.73 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2ATM | |
| SCHEMBL7086987 | 0.73 | MEN1 (0.51) | MEP1BMEP1AMEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL15067497 | 0.72 | FOLH1 (0.58) | MEP1BMEP1AMEN1KMT2AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | MEP1B 240/4885MEP1A 798/4885MEN1 3533/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | MEP1B 4059/4885MEP1A 4672/4885MEN1 4126/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | MEP1B 4581/4885MEP1A 4610/4885MEN1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.